A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects

This was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered SRSD107 in Chinese healthy subjects. SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.

NCT Number	NCT07655427
Lead Sponsor	Sirius Therapeutics Co., Ltd.
Conditions	Thrombus
Enrollment	48 participants
Start Date	2024-03-29
Primary Completion	2025-03-02 (estimated)
Study Completion	2025-03-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-17